Novo Nordisk And Hengrui Pharma Sign Exclusive Licence Deal For Once-Weekly Oral GLP-1/GIP Drug HRS-1596, Worth Up To $2.60B
Includes $300M Upfront Payment And Sales Royalties - Novo Gains Exclusive Global Rights Excluding China, Hong Kong, Macao And Taiwan - Hengrui Approved To Begin Phase 1 Trials In China